Drug Profile
MV NIS
Alternative Names: MV-NIS; Sodium Iodide Simporter Measles VirusLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Vyriad
- Developer Mayo Clinic; National Cancer Institute (USA); University of Arkansas System; Vyriad
- Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- No development reported Breast cancer; Medulloblastoma; Rhabdoid tumour; Squamous cell cancer; Urethral cancer
- Discontinued Glioblastoma; Haematological malignancies; Head and neck cancer; Malignant-mesothelioma; Multiple myeloma; Non-small cell lung cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease) in USA (Intratumoural, Injection)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Medulloblastoma(In adolescents, In children, In infants, Recurrent, Second-line therapy or greater, In adults) in USA (Intratumoural)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Rhabdoid-tumour(In adolescents, In children, In infants, Recurrent, Second-line therapy or greater, In adults) in USA (Intratumoural)